Angiomax Gains Second Label Expansion For 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplement cleared Nov. 30 allows use of the anticoagulant bivalirudin in percutaneous coronary intervention patients at risk for heparin-induced thrombocytopenia or thrombosis syndrome.